// App-Quantinova.ai

: Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).

Researchers

Presenter

  • Laura Cattaneo

Principal Investigators

  • Vincenzo Lagano

  • Laura Carpenito

  • Caterina Napolitano

  • Ilaria Bersani

  • Andrea Necchi

  • Nicola Nicolai

  • Biagio Paolini

  • Maurizio Colecchia

  • Massimo Milione

  • Giancarlo Pruneri

  • Roberta Mortarini

  • Andrea Anichini

  • Patrizia Giannatempo

Medical Centers

  • Human Tumors Immunobiology Unit - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • IRCCS National Cancer Institute,Milan,Italy

  • Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • 1st Pathology Division - Department of Pathology and Laboratory Medicine - IRCCS Foundation National Cancer Institute, Milano, Italy

  • Vita-Salute San Raffaele University, Milan, Italy

  • Vita-Salute University, IRCCS San Raffaele Hospital, Milan, Italy

  • University of Milan, Milan, Italy

  • University of Palermo, Palermo, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • beta-2 microglobulin

  • Cytokeratin 20

  • Cluster of Differentiation 163

  • Cluster of Differentiation 2AP

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Human Leukocyte Antigen – DR isotype

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT02736266

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved